Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab Revises Financial Guidance5 Nov 2009
Genmab Achieves Milestone in Arzerra Collaboration27 Oct 2009
GSK and Genmab Receive Accelerated Approval for Arzerra26 Oct 2009
Articles of Association22 Oct 2009
Major Shareholder Announcement13 Oct 2009
Declaratory Judgment Action Filed by GSK8 Oct 2009
Grant of Warrants to Employees in Genmab A/S8 Oct 2009
Genmab to Attend Four September Investor Conferences
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
2 Sept 2009
Genmab Announces Positive Top-Line Results for Arzerra TM in Front Line NHL26 Aug 2009
Interim Report for the 6 months ended June 30, 200918 Aug 2009
Genmab Announces 2009 First Half Year Results18 Aug 2009
GlaxoSmithKline and Genmab Announce Results from a Study of Arzerra in Rituximab Refractory Follicular NHL17 Aug 2009
  • Previous
  • 1
  • More pages
  • 104
  • 105
  • 106
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863